Qiagen N.V. stock faces pressure amid genomics slowdown as DACH investors eye biotech resilience

NodeGuardian · 2026-03-25T06:09:22+00:00

Qiagen N.V. shares fell following mixed Q4 2025 results, with a 2% revenue decline despite steady growth guidance for 2026. Investors are concerned about weaker genomics demand, though the diagnostics sector remains strong. DACH investors are watchful for recovery potential.

NodeGuardian

2026-03-25 06:09:22

Abstract generation in progress

Qiagen N.V. shares dipped after mixed Q4 2025 results revealed a 2% revenue decline and slower genomics demand. Despite maintaining its 2026 growth guidance, investors reacted to near-term softness in the genomics segment, though the diagnostics business showed resilience. DACH investors are closely monitoring the stock, given its significance in the European life sciences sector and the potential for recovery through renewed R&D funding and strategic expansions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.